| Name | Title | Contact Details |
|---|
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. In 2005, Astellas was formed by blending the talents, resources and passions of two highly successful firms - Yamanouchi and Fujisawa. Astellas aims to maintain and strengthen our position as the global leader in transplantation and urology areas, and going forward we are working to establish our position as a global category leader in oncology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate.
Adamis Pharmaceuticals Corporation is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Formex is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthon Pharmaceuticals Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.